Worldwide, each year more than 7 million people experience myocardial infarction, in which one-year mortality rates are now in the range of 10%, but vary with patient characteristics. The consequences are even more dramatic: among patients who survive, 20% suffer a second cardiovascular event in the first year and approximately 50% of major coronary events occur in those with a previous hospital discharge diagnosis of ischaemic heart disease.
The people behind these numbers spur this call for action. Prevention after myocardial infarction is crucial to reduce risk and suffering. Evidence-based interventions include optimal medical treatment with anti-platelets and statins, achievement of blood pressure, lipid and blood glucose targets, and appropriate lifestyle changes.
The European Society of Cardiology and its constituent bodies are determined to embrace this challenge by developing a consensus document in which the existing gaps for secondary prevention strategies are reviewed. Effective interventions in relation to the patients, healthcare providers and healthcare systems are proposed and discussed. Finally, innovative strategies in hospital as well as in outpatient and long-term settings are endorsed.
SmolinaKWrightFLRaynerM. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ2012; 344: d8059.
3.
PedersenFButrymovichVKelbaekH. Short- and long-term cause of death in patients treated with primary PCI for STEMI. J Am Coll Cardiol2014; 64: 2101–2108.
4.
VeldersMAJamesSKLibunganB. Prognosis of elderly patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention in 2001 to 2011: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) registry. Am Heart J2014; 167: 666–673.
5.
JernbergTHasvoldPHenrikssonM. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J2015; 36: 1163–1170.
6.
KontisVMathersCDBonitaR. Regional contributions of six preventable risk factors to achieving the 25 x 25 non-communicable disease mortality reduction target: a modelling study. Lancet Glob Health, Epub ahead of print 20October2015. DOI: 10.1016/S2214-109X(15)00179-5.
7.
WilsonKGibsonNWillanA. Effect of smoking cessation on mortality after myocardial infarction: metaanalysis of cohort studies. Arch Intern Med2000; 160: 939–944.
8.
EstruchRRosESalas-SalvadoJ.; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med2013; 368:1279–1290.
9.
YusufSHawkenSOunpuuS.; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet2004; 364(9438): 937–952.
10.
ChowCKJollySRao-MelaciniP. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation2010; 121: 750–758.
11.
KotsevaKWoodDDe BacquerD.; on behalf of the EUROASPIRE Investigators. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol2016; 23:1618–1627.
12.
UrbinatiSOlivariZGonziniL.: for the BLITZ-4 Investigators. Secondary prevention after acute myocardial infarction: drug adherence, treatment goals, and predictors of health lifestyle habits. The BLITZ-4 Registry. Eur J Prev Cardiol2015; 22: 1548–1556.
13.
PerkJDe BackerGGohlkeH. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J2012; 33: 1635–1701.
14.
PiepoliMFCorràUBenzerW. Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil2010; 17:1–17.
15.
PiepoliMFCorràUAdamopoulosS. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery. A policy statement from the Cardiac Rehabilitation Section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. Eur J Prev Cardiol2012; 21: 664–681.
Bjarnason-WehrensBMcGeeHZwislerAD.; Cardiac Rehabilitation Section European Association of Cardiovascular Prevention and Rehabilitation. Cardiac rehabilitation in Europe: results from the European Cardiac Rehabilitation Inventory Survey. Eur J Cardiovasc Prev Rehabil2010; 17: 410–418.
18.
VollerHReibisRSchwaabB. The ESC Textbook of Preventive Cardiology, Part 4. Setting and delivery of preventive cardiology. Hospital-based rehabilitation units. Oxford: Oxford University Press, 2015,pp.285–293.
19.
ConnollySCupplesM. The ESC Textbook of Preventive Cardiology, Part 4. Setting and delivery of preventive cardiology. Community-based prevention centres. Oxford: Oxford University Press, 2015, pp.312–319.
20.
WoodDAKotsevaKConnollyS.; on behalf of the EUROACTION Study Group. EUROACTION: a European Society of Cardiology demonstration project in preventive cardiology. A paired cluster randomised controlled trial of a multi-disciplinary family based preventive cardiology programme for coronary patients and asymptomatic high risk individuals. Lancet2008; 371: 1999–2012.
21.
GiannuzziPTemporelliPLMarchioliR. Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network. Arch Intern Med2008; 168: 2194–2204.
22.
FidanD1UnalBCritchleyJ. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010. Q J Med2007; 100(5): 277–289.
23.
OldridgeNBPakoshMTThomasRJ. Cardiac rehabilitation in low- and middle-income countries: a review on cost and cost-effectiveness. Int Health2016; 8: 77–82.
24.
BrownTHernandezABittnerV. Predictors of cardiac rehabilitation referral in coronary artery disease patients. J Am Coll Cardiol2009; 54: 515–521.
25.
KarmaliKNDaviesPTaylorF. Promoting patient uptake and adherence in cardiac rehabilitation. Cochrane Database Syst Rev2014; 6: CD007131.
26.
ClarkAKing-ShierKDuncanA. Factors influencing referral to cardiac rehabilitation and secondary prevention programs: a systematic review. Eur J Prev Cardiol2012; 20: 692–700.
27.
McCorryNKCorriganMTullyMA. Perceptions of exercise among people who have not attended cardiac rehabilitation following myocardial infarction. J Health Psychol2009; 14: 924–932.
28.
JackBWChettyVKAnthonyD. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med2009; 150: 178–187.
29.
PiepoliMFCorràUAbreuA. Cardiac Rehabilitation section of the European Association for Cardiovascular Prevention & Rehabilitation of the ESC. Challenges in secondary prevention of cardiovascular diseases: a review of the current practice. Int J Cardiol2015; 180: 114–119.
30.
ColeJASmithSMHartN. Do practitioners and friends support patients with coronary heart disease in lifestyle change? A qualitative study. BMC Fam Pract2013; 14: 126.
31.
NaderiSHBestwickJPWaldDS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med2012; 125: 882–887.
32.
CorraoGContiVMerlinoL. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. Clin Ther2010; 32: 300–310.
33.
AubertREYaoJXiaF. Is there a relationship between early statin compliance and a reduction in healthcare utilization?Am J Manag Care2010; 16: 459–466.
National Institute for Health and Care Excellence. Medicine optimisation: the safe and effective use of medicines to enable the best possible outcomes, www.nice.org.uk/guidance/ng5 (accessed 4 March 2015).
National Institute for Health and Care Excellence. Myocardial infarction: cardiac rehabilitation and prevention of further MI. Clinical guideline, www.nice.org.uk/guidance/cg172 (accessed 4 March 2015).
38.
GillebertTCBrooksNFontes-CarvalhoR. ESC Core Curriculum for the General Cardiologist (2013). Eur Heart J2013; 34: 2381–2411.
TaheriPAButzDAGreenfieldLJ. Length of stay has minimal impact on the cost of hospital admission. J Am Coll Surg2000; 191: 123–130.
41.
StegPGJamesSKAtarD.; Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J2012; 33: 2569–2619.
42.
MercadoMGSmithDKMcConnonML. Myocardial infarction: management of the subacute period. Am Family Physician2013; 88: 581–588.
43.
JackBWChettyVKAnthonyD. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med2009; 150: 178–187.
44.
ClancyCM. Reengineering hospital discharge: a protocol to improve patient safety, reduce costs, and boost patient satisfaction. Am J Med Qual2009; 24: 344–346.
45.
WachterRMGoldmanL. The hospitalist movement 5 years later. JAMA2002; 287: 487–494.
46.
ColemanEAMinSJChomiakA. Posthospital care transitions: patterns, complications, and risk identification. Health Serv Res2004; 39: 1449–1465.
47.
NieuwlaatRSchwalmJDKhatibR. Why are we failing to implement effective therapies in cardiovascular disease?Eur Heart J2013; 34: 1262–1269.
48.
CupplesMEMcKnightA. A five year follow-up study of patients at high cardiovascular risk who took part in a randomised controlled trial of health promotion. BMJ1999; 319: 687–688.
49.
Health & Social Care Information Centre. Quality and outcomes framework, http://www.hscic.gov.uk/qof(accessed 4 March 2015).
50.
PiepoliMFBinnoSCorràU. Committee on Exercise Physiology & Training of the Heart Failure Association of the ESC. ExtraHF survey: the first European survey on implementation of exercise training in heart failure patients. Eur J Heart Fail2015; 17: 631–638.
51.
HobbsFDJukemaJWDa SilvaPM. Barriers to cardiovascular disease risk scoring and primary prevention in Europe. Q J Med2010; 103: 727–739.
52.
ThomasRDennaT. The role of cardiac rehabilitation following acute coronary syndromes. Curr Cardiol Rep2014; 16: 534.
53.
GraceSRussellKReidR. Effect of cardiac rehabilitation referral strategies on utilization rates: a prospective, controlled study. Arch Intern Med2011; 171: 235–241.
54.
WestRRJonesDAHendersonAH. Rehabilitation after myocardial infarction trial (RAMIT): multi-centre randomised controlled trial of comprehensive cardiac rehabilitation in patients following acute myocardial infarction. Heart2012; 98: 637–644.
55.
CabanaMDRandCSPoweNR. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA1999; 282: 1458–1465.
56.
FrederixIVanheesLDendaleP. A review of telerehabilitation for cardiac patients. J Telemed Telecare2015; 21(1): 45–53.
57.
FrederixIHansenDConinxK. Medium-term effectiveness of a comprehensive internet-based and patient-specific telerehabilitation program with text messaging support for cardiac patients: randomized controlled trial. J Med Internet Res2015; 17: e185.
MyersVDroryYGerberY. Clinical relevance of frailty trajectory post myocardial infarction. Eur J Prev Cardiol2014; 21: 758–766.
60.
UchmanowiczILisiakMWontorR. Frailty syndrome in cardiovascular disease: clinical significance and research tools. Eur J Cardiovasc Nurs2015; 14: 303–309.
61.
BarraSProvidenciaRPaivaL. ACHTUNG-Rule: a new and improved model for prognostic assessment in myocardial infarction. Eur Heart J Acute Cardiovasc Care2012; 1: 320–336.
62.
TaylorRSDalalHJollyK. Home-based versus centre-based cardiac rehabilitation. Cochrane Database of Systematic Reviews2015, Issue 8. Art. No.: CD007130. DOI: 10.1002/14651858.CD007130.pub3.
63.
FrederixIHansenDConinxK. Effect of comprehensive cardiac telerehabilitation on one-year cardiovascular rehospitalization rate, medical costs and quality of life: a cost-effectiveness analysis. Eur J Prev Cardiol23: 674–682.
64.
CastellanoJMSanzGPeñalvoJL. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol2014; 64: 2071–2082.
65.
ColhounHMRobinsonJGFarnierM. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovasc Disord2014; 14: 121.
66.
CannonCPBlazingMAGiuglianoRP.; for the IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med2015; 372: 2387–2397.
67.
MauriLKereiakesDJYehRW.; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med2014; 371: 2155–2166.
68.
BonacaMPBhattDLCohenM.; PEGASUS TIMI 54 Steering Committee and Investigators. Longterm use of ticagrelor in patients with prior myocardial infarction. N Engl J Med2015; 372: 1791–1800.
69.
MegaJLBraunwaldEWiviottSD. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med2012; 366: 9–19.
70.
WilliamsBMacDonaldTMMorantS.; for The British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet2015; 386: 2059–2068.
71.
BrownMJWilliamsBMacDonaldTM. Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomized double-blind trial in patients with essential hypertension. BMJ Open2015; 5: e008086.
72.
The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med2015; 373: 2103–2116.
